Industry Symposia

All times are Central Standard Time.

All sessions will be held at the Gaylord Opryland Resort & Convention Center. Each session is free and includes breakfast. The AARC is not responsible for information presented at these sessions.

Monday, Nov. 6, 6:30 a.m.–8:30 a.m. | Presidential Ballroom A

Striking a Balance: Finding the Optimal Settings During HFNC Therapy

Jie Li, PhD, RRT, RRT-ACCS, FAARC

Provided by

Jie Li
Learning Objectives
  • Explore the diverse physiological effects of different flow settings during high-flow nasal cannula (HFNC) treatment, elucidating the association between flows and parameters such as oxygenation, carbon dioxide washout, and positive end-expiratory pressure.
  • Analyze the existing evidence by reviewing both in vitro and in vivo studies, aiming to discern the optimal range of flow settings that maximize therapeutic benefits while mitigating potential drawbacks, such as alveolar overdistention and patient discomfort.
  • Propose a patient-centered approach to individualizing flow settings within HFNC therapy, incorporating clinical indicators such as oxygenation, respiratory rates, the ROX index, and patient comfort, ultimately offering practical insights to guide clinicians in navigating the complexity of flow titration.

This course has been approved for Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care.

Tuesday, Nov. 7, 7:00 a.m.–8:00 a.m. | Presidential Ballroom A

Evidence-Based Reduction of VAP in the Trauma Patient Population

Marcelous Johnson, DHSc, MHA, BSc, BSN, RRT, RRT-NPS, CSSGB

The Future of Mechanical Ventilation Technology

Robert Chatburn, MHHS, RRT, RRT-NPS, FAARC

Provided by

Marcelous Johnson Robert Chatburn

This course has been approved for Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care.

Tuesday, Nov. 7, 6:30 a.m.–8:00 a.m. | Presidential Ballroom B

An Option for Patients with OCS Dependent Asthma

Maureen George PhD, AE-C, RN, FAAN

Provided by

The role that Dupixent plays in helping patients with OCS Dependent asthma reduce their OCS dose and improving asthma control. Please see Regeneron at booth 673 if you have any questions about this symposium.